95124-07-5Relevant articles and documents
CARBENE LIGANDS AS ANTHRACYCLINONESYNTHONS-II CHROMIUM MEDIATED CYCLOADDITION OF ALKYNES, CARBENES AND CARBON MONOXIDE: APPLICATION TO RING B SYNTHESIS IN ANTHRACYCLINONES
Doetz, Karl Heinz,Popall, Michael
, p. 5797 - 5802 (1985)
The cycloaddition of Cr-co-ordinated alkyne, carbene and carbonyl ligands provides a variable route to the anthracyclinone skeleton.The key step of a formal total synthesis of 4-demethoxydaunomycinone (1) is based on the reaction of carbonyl-carbene complex 15 -used as a CD ring synthon- and alkyne 9 leading to the formation of ring B.
Silver oxide(I) promoted Conia-ene/radical cyclization for a straightforward access to furan derivatives
Ardisson, Janick,Lannou, Marie-Isabelle,Mohamed, Selkti,Sorin, Geoffroy,Yu, Bao
supporting information, p. 1374 - 1377 (2022/02/11)
A novel access to fused furan cores using silver oxide(I) has been developed. Mechanistic investigations indicate the involvement of a Conia-ene reaction/radical cyclization for an expedient path to complex furan derivatives. The reaction is broad in scop
Iron-Catalyzed [2+2+2] Annulation of Aliphatic Bridged 1,n-Enynes with Aldehydes for the Synthesis of Fused Pyrans
Tian, Tian,Wang, Xin,Lv, Leiyang,Li, Zhiping
supporting information, p. 4425 - 4428 (2020/06/05)
An iron-catalyzed [2+2+2] annulation of aliphatic bridged 1,n-enynes with aldehydes was developed. Aldehydes play a dual role as the precursors of acyl radicals to trigger the cascade cyclization but also as the radical acceptors to terminate the annulation. This two-in-one strategy overcomes the limitation in [2+2+m] cyclization that requires a rigid benzene skeleton as the essential linker, thus enabling the efficient synthesis of functionalized fused [5.6] and [6.6] pyran skeletons.
SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS
-
Paragraph 0400; 0403-0404, (2020/12/25)
Disclosed are substituted heterocycle compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be utilized as therapeutics for treating cancer and cell proliferative disorders.